At the time of writing, Allogene Therapeutics Inc [ALLO] stock is trading at $5.46, up 10.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALLO shares have gain 17.93% over the last week, with a monthly amount glided 47.17%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference. In a post published today on Yahoo Finance, Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PT/9:10 a.m. ET.
From an analyst’s perspective:
Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on January 05, 2024, when JMP Securities downgraded its rating to a Mkt Perform. Previously, Guggenheim downgraded its rating to Neutral on January 05, 2024. On December 08, 2023, Citigroup initiated with a Buy rating and assigned a price target of $7 on the stock. Citigroup started tracking the stock assigning a Buy rating. Bernstein started tracking with a Mkt Perform rating for this stock on March 21, 2023, and assigned it a price target of $6. In a note dated January 24, 2023, JP Morgan upgraded an Overweight rating on this stock and revised its target price from $20 to $11.
For the past year, the stock price of Allogene Therapeutics Inc fluctuated between $2.23 and $6.89. Currently, Wall Street analysts expect the stock to reach $34.25 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $5.46 at the most recent close of the market. An investor can expect a potential return of 527.29% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
According to Allogene Therapeutics Inc [NASDAQ:ALLO], the company’s sales were 0.19M for trailing twelve months, which represents an -12.24% plunge. Gross Profit Margin for this corporation currently stands at -76.35% with Operating Profit Margin at -1822.24%, Pretax Profit Margin comes in at -1789.54%, and Net Profit Margin reading is -1779.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.54 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.05 points at the first support level, and at 4.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.67, and for the 2nd resistance point, it is at 5.88.
Allogene Therapeutics Inc [ALLO] reported earnings per share of -$0.37 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.52/share, meaning a difference of $0.15 and a surprise factor of 28.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.53 per share as compared to estimates of -$0.59 per share, a difference of $0.06 representing a surprise of 10.20%.
Ratios To Look Out For
It is important to note that Allogene Therapeutics Inc [NASDAQ:ALLO] has a current ratio of 12.58. In addition, the Quick Ratio stands at 12.58 and the Cash Ratio stands at 1.84. Considering the valuation of this stock, the price to sales ratio is 4835.84, the price to book ratio is 1.57.
Transactions by insiders
Recent insider trading involved MESSEMER DEBORAH M., Director, that happened on Dec 18 when 18640.0 shares were sold. Director, Mayo Stephen completed a deal on Aug 07 to sell 10000.0 shares.
